Comparative Pharmacology
Head-to-head clinical analysis: TANZEUM versus VICTOZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TANZEUM versus VICTOZA.
TANZEUM vs VICTOZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneous injection: 300 mg every 4 weeks. Administer as 3 consecutive injections of 100 mg each in the same body region (abdomen, thigh, or upper arm).
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
None Documented
None Documented
Terminal elimination half-life approximately 5 days (range 4-6 days), supporting weekly subcutaneous dosing
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Renal (79% as unchanged drug), biliary/fecal (minor, ~1%)
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist